AOD 9604 Peptide: What is it?
The AOD 9604 is a synthetic version of the C-terminus (176-191) of growth hormone (HGH). By increasing lipolysis and decreasing lipogenesis, this hexadecapeptide has suggested impressive potential in lipid metabolism.
Studies suggest that AOD 9604 may enhance fat breakdown by focusing on fat-rich regions while leaving the rest of the metabolic profile alone.
In the past, AOD 9604’s potential to reduce fat deposition made it a widely studied compound in obesity research. Furthermore, research indicates there may be little chance of acquiring glucose intolerance and diabetes mellitus since AOD 9604 does not seem to influence insulin and IGF-1 levels.
Semaglutide Peptide: What is it?
Despite its classification as a peptide, Semaglutide is best recognized as an agonist for the GLP-1 receptor. Investigations purport that it may stimulate the incretin glucagon-like peptide-1 (GLP-1).
Findings imply that in response to elevated blood sugar levels, Semaglutide may facilitate the pancreas’s secretion of an adequate quantity of insulin. Therefore, it may aid in the proper production of insulin by the organism.
Keeping the sugar levels consistently high may have serious consequences within the organism; this approach has been hypothesized to aid in preventing them. Inflammation, excess fat storage, and cardiovascular disease are all theorized to be linked to high blood sugar.
AOD 9604 and Semaglutide Peptide Blend
The weight research community has been abuzz by research findings combining AOD 9604 and Semaglutide in weight reduction research.
This blend has been speculated to help reduce excess weight by enhancing insulin sensitivity and targeting fat cells, especially those in visceral adipose tissue. Studies suggest that AOD 9604 and Semaglutide may impact the pituitary gland and growth hormone synthesis, influence blood sugar, and promote muscle cell development.
Research indicates that combining these two chemicals may have the dual impact of suppressing hunger and encouraging weight loss by binding to certain receptors.
Investigations purport that this peptide blend may also help reduce blood sugar levels and enhance heart function; it was created primarily to address weight control. Further, promoting lipolysis and inhibiting lipogenesis may aid in fat reduction.
AOD 9604 and Semaglutide Peptide Blend: Mechanism of Action
The peptide AOD 9604 is an analog of hGH or growth hormone. Its primary action mechanism is believed to be its potential to enhance fat metabolism and breakdown. Findings imply that AOD 9604 may block fat cell breakdown and release fatty acids for energy by acting similarly to the effects of the naturally occurring hormone lipoprotein lipase (LPL).
In contrast, Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has recently been studied for its impacts in the context of type 2 diabetes and, more specifically, in chronic obesity.
One of the main potentials of Semaglutide is believed to be to imitate the effects of GLP-1, a hormone that is produced naturally.
While that gives the big picture of how this blend may work internally, let’s understand how AOD 9604 and Semaglutide may aid in the context of minimally invasive weight reduction.
AOD 9604 and Semaglutide Peptide Blend: Weight
Scientists speculate that by increasing the breakdown of fatty tissue, AOD 9604 may target stubborn fat deposits, making it more accessible for energy expenditure. It has been theorized that this peptide does not appear to encourage muscle atrophy and may have no discernible effect on other organs or tissues.
The supposition that AOD 9604 is believed to target fat cells specifically may make it a favorable weight reduction approach in research studies.
Studies suggest that because it may mediate weight loss in two ways, blending Semaglutide with AOD 9604 might become a valuable blend for further research consideration.
The hypothalamus is a brain area that regulates hunger and food consumption; Semaglutide has been hypothesized to impact this area. Because it is believed to heighten the sensation of fullness, Semaglutide may reduce food intake due to appetite supression. The small intestine does not seem to get its contents as quickly as it would with Semaglutide.
Research indicates that a delay in stomach emptying aids the sensation of fullness and regulates blood sugar levels after a meal. Semaglutide has also been speculated to control blood sugar levels by lowering them, boosting insulin secretion and sensitivity, and decreasing glucagon.
Animal models exposed to Semaglutide usually appear to lose weight because it has been reported to improve insulin sensitivity, control appetite, delay stomach emptying, and improve blood sugar management.
Visit biotechpeptides.com if you are a researcher interested in buying high-quality AOD 9604 or Semaglutide from a reliable, cost-appropriate source.
Feature image by felixioncool on Pixabay
References
[i] Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1442-9. doi: 10.1038/sj.ijo.0801740. PMID: 11673763.
[ii] Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004 Apr;5(4):436-40. PMID: 15134286.
[iii] Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi: 10.1159/000053183. PMID: 11146367.
[iv] Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi: 10.1210/endo.142.12.8522. PMID: 11713213.
[v] Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2. PMID: 33667417.
[vi] Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. PMID: 34942372; PMCID: PMC9209591.
[vii] Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022 Jan;70(1):5-13. doi: 10.1136/jim-2021-001952. Epub 2021 Oct 27. PMID: 34706925; PMCID: PMC8717485.
[viii] Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O’Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831. PMID: 33625476; PMCID: PMC7905697.
